Log in

Start Your Membership Now

Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with products approved by the U.S. Food and Drug Administration for the treatment of attention deficit hyperactivity disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (KYE), a private company headquartered in Mississauga, Ontario and focused on the Canadian market, announced that they have entered into an agreement whereby KYE received exclusive rights to commercialize Tris’ FDA-approved ADHD product portfolio in Canada.  Under the terms of this agreement, KYE will also handle all ongoing Canadian regulatory activities for the products. Financial terms of the agreement were not disclosed.

Doug Reynolds . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Service & Treatment Updates

Categories
All Bulletins
Submit a Bulletin
  • This field is for validation purposes and should be left unchanged.
  • Max. file size: 98 MB.